Giulia Veronesi
Overview
Explore the profile of Giulia Veronesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
328
Citations
4048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DAmico F, Dormio S, Veronesi G, Guarracino F, Donadello K, Cinnella G, et al.
Br J Anaesth
. 2025 Feb;
PMID: 39919985
Background: Prehabilitation aims to enhance preoperative functional capacity through exercise, nutrition, and psychological programs. Home-based prehabilitation represents an alternative to hospital prehabilitation, with the advantage of not utilising hospital resources....
2.
Hendriks L, Remon J, Faivre-Finn C, Garassino M, Heymach J, Kerr K, et al.
Nat Rev Dis Primers
. 2025 Jan;
11(1):3.
PMID: 39773998
No abstract available.
3.
Broseghini E, Veronesi G, Gardini A, Venturi F, Scotti B, Vespi L, et al.
Arch Dermatol Res
. 2024 Dec;
317(1):78.
PMID: 39643819
Since melanoma incidence is steadily increasing, guidelines regarding the diagnosis, staging, and treatment of melanoma are constantly being updated. In particular, the use of adjuvant therapy in stage IIb/c melanoma...
4.
Broseghini E, Venturi F, Veronesi G, Scotti B, Migliori M, Marini D, et al.
Pigment Cell Melanoma Res
. 2024 Nov;
38(1):e13210.
PMID: 39609109
Cutaneous melanoma (CM) and pancreatic cancer are aggressive tumors whose incidences are rapidly increasing in the last years. This review aims to provide a complete and update description about mutational...
5.
Venturi F, Veronesi G, Scotti B, Dika E
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518117
Background/objectives: The landscape of advanced melanoma treatments has shifted dramatically in recent years. Target therapy and immunotherapy have changed the management of patients with both metastatic (stage IV according to...
6.
Dika E, Venturi F, Veronesi G, Veneziano L, Scotti B
Exp Dermatol
. 2024 Oct;
33(10):e15188.
PMID: 39367572
External ear lentigo maligna/lentigo melanoma (LM/LMM) represents approximately 1%-4% of all primary cutaneous melanomas. Over the past 20 years, dermoscopy has proven highly effective in early detection of LM/LMM, with...
7.
Hendriks L, Remon J, Faivre-Finn C, Garassino M, Heymach J, Kerr K, et al.
Nat Rev Dis Primers
. 2024 Sep;
10(1):71.
PMID: 39327441
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially...
8.
Dika E, Fanti P, Baraldi C, Venturi F, Scotti B, Veronesi G, et al.
Skin Res Technol
. 2024 Sep;
30(9):e70051.
PMID: 39258794
No abstract available.
9.
Venturi F, Erbacci V, Veronesi G, Scotti B, Baraldi C, Dika E
Skin Res Technol
. 2024 Aug;
30(8):e70012.
PMID: 39137046
Background: Basosquamous carcinoma (BSC) is a rare and aggressive nonmelanoma skin cancer (NMSC) that exhibits features of both BCC and squamous cell carcinoma (SCC). The gold standard for diagnosis is...
10.
Battista R, Pini G, Finco A, Corso F, Galli A, Arrigoni G, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123486
Background: The interplay between cancer cells and the immune system is crucial in cancer progression and treatment. In this regard, the tumor immune microenvironment and macroenvironment, marked by systemic inflammation...